Acute necrotizing hemorrhagic leukoencephalitis
Acute hemorrhagic leukoencephalitis of Weston Hurst is at the extreme end of the spectrum of demyelinating diseases. It typically follows a viral upper
Mar. 26, 2021
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Autoimmune glial fibrillary acidic protein astrocytopathy is a form of monophasic or relapsing steroid-responsive meningoencephalomyelitis often accompanied by a hallmark radial periventricular brain MRI enhancement pattern and inflammatory cerebrospinal fluid with lymphocytic pleocytosis. GFAP-IgG was first described at Mayo Clinic, U.S. and subsequently confirmed by multiple international groups (22).
• Autoimmune GFAP astrocytopathy manifests as a meningoencephalomyelitis (or limited form thereof) with dramatic steroid-responsiveness. Early relapses may occur if steroids are deescalated and discontinued quickly.
• Brain MRI may reveal a typical pattern of radial gadolinium enhancement; the spine MRI abnormalities are often hazy and longitudinally-extensive T2 hyperintensities with central cord enhancement.
• CSF testing for GFAP-IgG is more specific. Both the characteristic astrocytic, filamentous immunofluorescence pattern of CNS tissue staining (meeting all criteria) and positivity for GFAP-alpha isoform-specific-IgG are required for diagnosis.
• In most cases the etiology is unknown; in 25% of patients a neoplasm is detected after neurologic symptoms onset (most common being ovarian teratoma).
In 1999, Uchida and colleagues identified glial fibrillary acidic protein antibodies in the serum and cerebrospinal fluid samples of 2 pug dogs with canine necrotizing encephalitis, a severe and rapidly progressive form of encephalitis characterized by mood alteration, ataxia and seizures, and features of necrosis and lymphocytic inflammation in pathological studies (21). Further studies confirmed the presence of GFAP-IgG in larger cohorts with similar clinical phenotype (18).
In humans, GFAP-IgG was described as a biomarker of meningoencephalomyelitis in 2016 by Fang and associates in a cohort of 16 patients who presented with subacute cognitive and behavioral impairment, inflammatory CSF, pathology consistent with lymphocytic inflammation, and robust steroid therapy-responsiveness (06). Some of those cases had been previously reported, though utilizing pathologic descriptors for nomenclature, such as “nonvasculitic autoimmune inflammatory meningoencephalitis (NAIM)” (02) or “chronic microglial encephalomyelitis” (01).
Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.